A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity

Study Summary

The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks.

Conditions

Healthy Obesity Overweight

Interventions / Drugs

LY3549492

View on ClinicalTrials.gov ↗

Sponsor

LLY

Eli Lilly and Company

Diabetes/Oncology

C53/100

Study Details

Enrollment120 participants

Primary Completion—

Lead SponsorEli Lilly and Company

Data Retrieved2026-04-11 02:55:33.866601+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.